Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) EBIT Margin (2019 - 2025)

Legend Biotech filings provide 7 years of EBIT Margin readings, the most recent being 6.43% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 3609.0% to 6.43% in Q4 2025 year-over-year; TTM through Dec 2025 was 54.65%, a 234.0% decrease, with the full-year FY2025 number at 13.27%, up 3607.0% from a year prior.
  • EBIT Margin hit 6.43% in Q4 2025 for Legend Biotech, up from 15.96% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 596.51% in Q2 2022 to a low of 97962.57% in Q1 2021.
  • Median EBIT Margin over the past 5 years was 211.37% (2023), compared with a mean of 4681.98%.
  • Biggest five-year swings in EBIT Margin: tumbled -9845134bps in 2021 and later surged 9820825bps in 2022.
  • Legend Biotech's EBIT Margin stood at 230.36% in 2021, then skyrocketed by 72bps to 395.35% in 2022, then plummeted by -85bps to 57.62% in 2023, then tumbled by -174bps to 42.52% in 2024, then surged by 85bps to 6.43% in 2025.
  • The last three reported values for EBIT Margin were 6.43% (Q4 2025), 15.96% (Q3 2025), and 132.48% (Q2 2025) per Business Quant data.